KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Emergent BioSolutions (EBS) Accumulated Depreciation & Amortization (2016 - 2026)

Emergent BioSolutions has reported Accumulated Depreciation & Amortization over the past 16 years, most recently at $23.5 million for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization fell 7.48% year-over-year to $23.5 million; the TTM value through Mar 2026 reached $23.5 million, down 7.48%, while the annual FY2025 figure was $95.8 million, 11.95% down from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2026 was $23.5 million at Emergent BioSolutions, down from $95.8 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $143.3 million in Q4 2022 and troughed at $23.5 million in Q1 2026.
  • A 5-year average of $71.9 million and a median of $72.3 million in 2025 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 21.81% in 2022 and later dropped 19.36% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $143.3 million in 2022, then dropped by 12.7% to $125.1 million in 2023, then fell by 13.03% to $108.8 million in 2024, then dropped by 11.95% to $95.8 million in 2025, then plummeted by 75.47% to $23.5 million in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for EBS at $23.5 million in Q1 2026, $95.8 million in Q4 2025, and $72.3 million in Q3 2025.